SARS-CoV-2 replication–transcription complex (RTC)

The **SARS-CoV-2 replication–transcription complex** is a dynamic, membrane-associated assembly of non-structural viral proteins, derived from polyprotein processing, that orchestrate the replication and transcription of the viral RNA genome. The core components include **RNA-dependent RNA polymerase (nsp12)**, aided by **cofactors nsp7 and nsp8** for processivity, **helicase (nsp13)** for unwinding, **exoribonuclease (nsp14)** for error correction, and enzymes for RNA capping and methylation such as **nsp14 and nsp16**[1][2][5][6]. The machinery forms specialized structures called replication organelles (double-membrane vesicles) to shield viral RNA from host immune sensors[1][2][3]. This ensemble is a highly validated therapeutic target for antiviral drugs, especially inhibitors of **RdRp**, which have shown clinical efficacy in treating COVID-19[5]. Because the machinery consists of multiple protein subunits rather than a singular receptor or enzyme, “SARS-CoV-2 replication machinery” is best understood as a *collective target* comprising several distinct molecular elements[2][5]. The term as used is not a single canonical molecular entity, but denotes a recognized therapeutic target. It includes a spectrum of enzymes whose inhibition halts viral replication and disease progression in COVID-19[1][2][5].

Other names

Coronavirus RTCSARS-CoV-2 replication complexSARS-CoV-2 replicase machinery

Inhibition of viral RNA polymerase (e.g., nucleoside analogue incorporation stalling replication); Inhibition of RNA proofreading (targeting exonuclease); Inhibition of accessory protein functions (e.g., methyltransferase/capping).